CCL

Összesen 13 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM120117
035-os BibID:(WoS)001060565600002 (Scopus)85181657414
Első szerző:Ahmed, Sakir
Cím:Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis : survival analysis from a multicentre international patient?reported survey / Sakir Ahmed, Latika Gupta, Masataka Kuwana, John D. Pauling, Jessica Day, Naveen Ravichandran, Mrudula Joshi, Ioannis Parodis, Parikshit Sen, Kshitij Jagtap, Elena Nikiphorou, Sreoshy Saha, Vishwesh Agarwal, Tulika Chatterjee, James B. Lilleker, Sinan Kardes, Marcin Milchert, Tamer Gheita, Babur Salim, Tsvetelina Velikova, Abraham Edgar Gracia?Ramos, Ai Lyn Tan, Arvind Nune, Lorenzo Cavagna, Miguel A. Saavedra, Samuel Katsuyuki Shinjo, Nelly Ziade, Johannes Knitza, Oliver Distler, Suryo Anggoro Kusumo Wibowo, COVAD Study Group
Dátum:2023
ISSN:0172-8172 1437-160X
Megjegyzések:This study aimed to assess the incidence, predictors, and outcomes of breakthrough infection (BI) following coronavirus disease (COVID-19) vaccination in patients with systemic sclerosis (SSc), a risk group associated with an immune-suppressed state and high cardiopulmonary disease burden. Cross-sectional data from fully vaccinated respondents with SSc, non-SSc autoimmune rheumatic diseases (AIRDs), and healthy controls (HCs) were extracted from the COVAD database, an international self-reported online survey. BI was defined according to the Centre for Disease Control definition. Infection-free survival was compared between the groups using Kaplan-Meier curves with log-rank tests. Cox proportional regression was used to assess the association between BI and age, sex, ethnicity, and immunosuppressive drugs at the time of vaccination. The severity of BI in terms of hospitalization and requirement for oxygen supplementation was compared between groups. Of 10,900 respondents, 6836 fulfilled the following inclusion criteria: 427 SSc, 2934 other AIRDs, and 3475 HCs. BI were reported in 6.3% of SSc, 6.9% of non-SSc AIRD, and 16.1% of HCs during a median follow-up of 100 (IQR: 60-137) days. SSc had a lower risk for BI than HC [hazard ratio (HR): 0.56 (95% CI 0.46-0.74)]. BIs were associated with age [HR: 0.98 (0.97-0.98)] but not ethnicity or immunosuppressive drugs at the time of vaccination. Patients with SSc were more likely to have asymptomatic COVID-19, but symptomatic patients reported more breathlessness. Hospitalization [SSc: 4 (14.8%), HCs: 37 (6.6%), non-SSc AIRDs: 32(15.8%)] and the need for oxygenation [SSc: 1 (25%); HC: 17 (45.9%); non-SSc AIRD: 13 (40.6%)] were similar between the groups. The incidence of BI in SSc was lower than that in HCs but comparable to that in non-SSc AIRDs. The severity of BI did not differ between the groups. Advancing age, but not ethnicity or immunosuppressive medication use, was associated with BIs.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Breakthrough infections
COVAD
COVID-19
Surveys and questionnaires
Systemic sclerosis
Megjelenés:Rheumatology International. - 44 : 1 (2023), p. 89-97. -
További szerzők:Gupta, Latika Kuwana, Masataka Pauling, John D. Day, Jessica Ravichandran, Naveen Joshi, Mrudula Parodis, Ioannis Sen, Parikshit Jagtap, Kshitij Nikiphorou, Elena (reumatológus) Saha, Sreoshy Agarwal, Vishwesh Chatterjee, Tulika Lilleker, James B. Kardes, Sinan Milchert, Marcin Gheita, Tamer A. Salim, Babur Velikova, Tsvetelina Gracia-Ramos, Abraham Edgar Tan, Ai Lyn Nune, Arvind Cavagna, Lorenzo Saavedra, Miguel A. Shinjo, Samuel Katsuyuki Ziade, Nelly Knitza, Johannes Distler, Oliver Wibowo, Suryo Anggoro Kusumo Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM120111
035-os BibID:(Scopus)000972023600001
Első szerző:Ali, Sasha Saadia
Cím:Flares after COVID-19 infection in patients with idiopathic inflammatory myopathies : results from the COVAD study / Ali Sasha Saadia, R. Naveen, Sen Parikshit, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Edgar Gracia-Ramos Abraham, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Rojas Serrano Jorge, La Torre Ignacio García-De, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akawatcharangura, Shumnalieva Russka, Hoff Leonardo Santos, El Kibbi Lina, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo Vinicio, Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:2023
ISSN:1462-0324 1462-0332
Tárgyszavak:Orvostudományok Klinikai orvostudományok levél
folyóiratcikk
Megjelenés:Rheumatology. - 62 : 9 (2023), p. e263-e268. -
További szerzők:R., Naveen Sen, Parikshit Day, Jessica Joshi, Mrudula Nune, Arvind Nikiphorou, Elena (reumatológus) Saha, Sreoshy Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Jagtap, Kshitij Parodis, Ioannis Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Chen, Yi Ming Makol, Ashima Agarwal, Vishwesh Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Zamora Tehozol, Erick Adrian Rojas Serrano, Jorge La Torre, Ignacio García-De Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Hoff, Leonardo Santos El Kibbi, Lina Halabi, Hussein Vaidya, Binit Shaharir, Syahrul Sazliyana Hasan, A. T. M. Tanveer Dey, Dzifa Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Distler, Oliver Saavedra, Miguel A. Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM117878
035-os BibID:(WOS)001051657500001
Első szerző:Andreoli, Laura
Cím:COVID-19 vaccine safety during pregnancy and breastfeeding in women with autoimmune diseases : results from the COVAD study / Andreoli Laura, Lini Daniele, Schreiber Karen, Parodis Ioannis, Sen Parikshit, Ravichandran Naveen, Day Jessica, Joshi Mrudula, Jagtap Kshitij, Nune Arvind, Nikiphorou Elena, Agarwal Vishwesh, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Gracia-Ramos, Abraham Edgar, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Makol Ashima, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Serrano Jorge Rojas, De La Torre Ignacio García, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Akarawatcharangura Goo Phonpen, Shumnalieva Russka, Chen Yi-Ming, Hoff Leonardo Santos, El Kibbi Lina, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Toro Gutiérrez Carlos Enrique, Caballero-Uribe Carlo V., Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Saavedra Miguel A., Distler Oliver, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:2023
ISSN:1462-0324 1462-0332
Megjegyzések:Objectives: We investigated COVID-19 vaccine safety in pregnant and breastfeeding women with autoimmune diseases (AID) in the COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. Methods: Delayed-onset (>7 days) vaccine-related adverse events (AE), disease flares (DF), and AID-related treatment modifications were analyzed upon diagnosis of AID versus healthy controls (HC) and the pregnancy/breastfeeding status at the time of at least one dose of vaccine. Results: Among the 9201 participants to the self-administered online survey, 6787 (73.8%) were women. Forty pregnant and 52 breastfeeding patients with AID were identified, of whom the majority had received at least one dose of COVID-19 vaccine (100% and 96.2%, respectively). AE were reported significantly more frequently in pregnant than in non-pregnant patients (overall AE 45% vs 26%, p= 0.01; minor AE 40% vs 25.9%, p= 0.03; major AE 17.5% vs 4.6%, p< 0.01), but no difference was found in comparison with pregnant HC. No difference was observed between breastfeeding patients and HC with respect to AE. Post-vaccination DF were reported by 17.5% of pregnant and 20% of breastfeeding patients, and by 18.3% of age- and disease-matched non-pregnant and non-breastfeeding patients (n = 262). All pregnant/breastfeeding patients who experienced a DF were managed with glucocorticoids; 28.6% and 20% of them required initiation or change in immunosuppressants, respectively. Conclusion: This study provides reassuring insights into the safety of COVID-19 vaccines administered to women with AID during the gestational and post-partum periods, helping overcome hesitant attitudes, as the benefits for the mother and the fetus by passive immunization appear to outweigh potential risks.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19 vaccination
adverse events
autoimmune diseases
breastfeeding
disease flare
pregnancy
treatment
Megjelenés:Rheumatology. - [Epub ahead of print] (2023). -
További szerzők:Lini, Daniele Schreiber, Karen Parodis, Ioannis Sen, Parikshit Ravichandran, Naveen Day, Jessica Joshi, Mrudula Jagtap, Kshitij Nune, Arvind Nikiphorou, Elena (reumatológus) Agarwal, Vishwesh Saha, Sreoshy Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Makol, Ashima Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Zamora Tehozol, Erick Adrian Serrano, Jorge Rojas De La Torre, Ignacio García Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Chen, Yi-Ming Hoff, Leonardo Santos El Kibbi, Lina Halabi, Hussein Vaidya, Binit Shaharir, Syahrul Sazliyana Hasan, A. T. M. Tanveer Dey, Dzifa Toro Gutiérrez, Carlos Enrique Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Saavedra, Miguel A. Distler, Oliver Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM105682
035-os BibID:(Scopus)85160969875 (WoS)000892566100001
Első szerző:Andreoli, Laura
Cím:COVID-19 vaccine safety during the antenatal period in women with idiopathic inflammatory myopathies / Andreoli Laura, Sen Parikshit, Lini Daniele, Vincze Melinda Nagy, Schreiber Karen, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:2023
ISSN:1462-0324 1462-0332
Megjegyzések:Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
Tárgyszavak:Orvostudományok Klinikai orvostudományok levél
folyóiratcikk
Autoimmune diseases
COVID-19
Long-term adverse effects
Registries
Vaccination
Megjelenés:Rheumatology. - 62 : 6 (2023), p. e175-e179. -
További szerzők:Sen, Parikshit Lini, Daniele Nagy-Vincze Melinda (1985-) (orvos) Schreiber, Karen Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM120116
035-os BibID:(Scopus)85170690960 (WoS)001066356100001
Első szerző:Chatterjee, Tulika
Cím:Type 1 diabetes, COVID-19 vaccines and short-term safety : subgroup analysis from the global COVAD study / Tulika Chatterjee, Naveen Ravichandran, Narmadha Nair, Abraham Edgar Gracia-Ramos, Bhupen Barman, Parikshit Sen, Mrudula Joshi, Sreoshy Saha, Arvind Nune, Arun Kumar R. Pande, Tsvetelina Velikova, Ioannis Parodis, Ai Lyn Tan, Samuel Katsuyuki Shinjo, Hiya Boro, Vikas Agarwal, Rohit Aggarwal, Latika Gupta, COVAD Study Group
Dátum:2023
ISSN:2040-1116 2040-1124
Megjegyzések:Aims/introduction: Coronavirus disease 2019 (COVID-19) vaccinations have been proven to be generally safe in healthy populations. However, the data on vaccine safety in patients with type 1 diabetes are scarce. This study aimed to evaluate the frequency and severity of short-term (<7-day) adverse vaccination events (AEs) and their risk factors among type 1 diabetes patients. Materials and methods: This study analyzed data from the COVID-19 vaccination in Autoimmune Diseases (COVAD) survey database (May to December 2021; 110 collaborators, 94 countries), comparing <7-day COVID-19 vaccine AE among type 1 diabetes patients and healthy controls (HCs). Descriptive statistics; propensity score matching (1:4) using the variables age, sex and ethnicity; and multivariate analyses were carried out. Results: This study analyzed 5,480 completed survey responses. Of all responses, 5,408 were HCs, 72 were type 1 diabetes patients (43 females, 48.0% white European ancestry) and Pfizer was the most administered vaccine (39%). A total of 4,052 (73.9%) respondents had received two vaccine doses. Patients with type 1 diabetes had a comparable risk of injection site pain, minor and major vaccine AEs, as well as associated hospitalizations to HCs. However, type 1 diabetes patients had a higher risk of severe rashes (3% vs 0.4%, OR 8.0, 95% confidence interval 1.7-36), P = 0.007), although reassuringly, these were rare (n = 2 among type 1 diabetes patients). Conclusions: COVID-19 vaccination was safe and well tolerated in patients with type 1 diabetes with similar AE profiles compared with HCs, although severe rashes were more common in type 1 diabetes patients.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19
Type-1 diabetes mellitus
Vaccine
Megjelenés:Journal of Diabetes Investigation. - 15 : 1 (2023), p. 131-138. -
További szerzők:Ravichandran, Naveen Nair, Narmadha Gracia-Ramos, Abraham Edgar Barman, Bhupen Sen, Parikshit Joshi, Mrudula Saha, Sreoshy Nune, Arvind Pande, Arunkumar R. Velikova, Tsvetelina Parodis, Ioannis Tan, Ai Lyn Shinjo, Samuel Katsuyuki Boro, Hiya Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

6.

001-es BibID:BIBFORM117879
035-os BibID:(scopus)85162972096 (wos)001014747300001
Első szerző:Doskaliuk, Bohdana
Cím:Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies : results from the COVAD study / Doskaliuk Bohdana, Ravichandran Naveen, Sen Parikshit, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Gracia-Ramos Abraham Edgar, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Tehozol Erick Adrian Zamora, Serrano Jorge Rojas, La Torre Ignacio García-De, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akarawatcharangura, Shumnalieva Russka, Hoff Leonardo Santos, Kibbi Lina El, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo V., Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., COVAD study group, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika
Dátum:2023
ISSN:0172-8172 1437-160X
Megjegyzések:Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb-June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35-58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2-7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. These observations may inform guidelines to identify high-risk patients warranting close monitoring in the post-vaccination period.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Adverse event
Autoimmunity
COVID-19
Myositis
Surveys and questionnaires
Vaccination
Megjelenés:Rheumatology International. - 43 : 9 (2023), p. 1651-1664. -
További szerzők:Ravichandran, Naveen Sen, Parikshit Day, Jessica Joshi, Mrudula Nune, Arvind Nikiphorou, Elena (reumatológus) Saha, Sreoshy Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Jagtap, Kshitij Parodis, Ioannis Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Chen, Yi Ming Makol, Ashima Agarwal, Vishwesh Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Tehozol, Erick Adrian Zamora Serrano, Jorge Rojas La Torre, Ignacio García-De Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Hoff, Leonardo Santos Kibbi, Lina El Halabi, Hussein Vaidya, Binit Shaharir, Syahrul Sazliyana Hasan, A. T. M. Tanveer Dey, Dzifa Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Distler, Oliver Saavedra, Miguel A. Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

7.

001-es BibID:BIBFORM105749
035-os BibID:(scopus)85139571711 (wos)000840395200001
Első szerző:Fazal, Zoha Zahid
Cím:COVAD survey 2 long-term outcomes : unmet need and protocol / Fazal Zoha Zahid, Sen Parikshit, Joshi Mrudula, Ravichandran Naveen, Lilleker James B., Agarwal Vishwesh, Kardes Sinan, Kim Minchul, Day Jessica, Makol Ashima, Milchert Marcin, Gheita Tamer, Salim Babur, Velikova Tsvetelina, Gracia-Ramos Abraham Edgar, Parodis Ioannis, Nikiphorou Elena, Tan Ai Lyn, Chatterjee Tulika, Cavagna Lorenzo, Saavedra Miguel A., Shinjo Samuel Katsuyuki, Ziade Nelly, Selva-O'Callaghan Albert, Nune Arvind, Knitza Johannes, Kuwana Masataka, Gutiérrez Carlos-Enrique Toro, Caballero-Uribe Carlo Vinicio, Dey Dzifa, Distler Oliver, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika, COVAD Study Group
Dátum:2022
ISSN:0172-8172 1437-160X
Megjegyzések:Vaccine hesitancy is considered a major barrier to achieving herd immunity against COVID-19. While multiple alternative and synergistic approaches including heterologous vaccination, booster doses, and antiviral drugs have been developed, equitable vaccine uptake remains the foremost strategy to manage pandemic. Although none of the currently approved vaccines are live-attenuated, several reports of disease flares, waning protection, and acute-onset syndromes have emerged as short-term adverse events after vaccination. Hence, scientific literature falls short when discussing potential long-term effects in vulnerable cohorts. The COVAD-2 survey follows on from the baseline COVAD-1 survey with the aim to collect patient-reported data on the long-term safety and tolerability of COVID-19 vaccines in immune modulation. The e-survey has been extensively pilot-tested and validated with translations into multiple languages. Anticipated results will help improve vaccination efforts and reduce the imminent risks of COVID-19 infection, especially in understudied vulnerable groups.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Autoimmune diseases
COVID-19
Long-term adverse effects
Registries
Vaccination
Megjelenés:Rheumatology International. - 42 : 12 (2022), p. 2151-2158. -
További szerzők:Sen, Parikshit Joshi, Mrudula Ravichandran, Naveen Lilleker, James B. Agarwal, Vishwesh Kardes, Sinan Kim, Minchul Day, Jessica Makol, Ashima Milchert, Marcin Gheita, Tamer A. Salim, Babur Velikova, Tsvetelina Gracia-Ramos, Abraham Edgar Parodis, Ioannis Nikiphorou, Elena (reumatológus) Tan, Ai Lyn Chatterjee, Tulika Cavagna, Lorenzo Saavedra, Miguel A. Shinjo, Samuel Katsuyuki Ziade, Nelly Selva-O'Callaghan, Albert Nune, Arvind Knitza, Johannes Kuwana, Masataka Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Dey, Dzifa Distler, Oliver Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

8.

001-es BibID:BIBFORM120118
035-os BibID:(WoS)000886025900001 (Scopus)85149134170
Első szerző:Naveen, R.
Cím:COVID-19 vaccination in autoimmune diseases (COVAD) study : vaccine safety and tolerance in rheumatoid arthritis / Naveen R., Ioannis Parodis, Mrudula Joshi, Parikshit Sen, Julius Lindblom, Vishwesh Agarwal, James B. Lilleker, Ai Lyn Tan, Arvind Nune, Samuel Katsuyuki Shinjo, Babur Salim, Nelly Ziade, Tsvetelina Velikova, Abraham Edgar Gracia-Ramos, Miguel A. Saavedra, Jessica Day, Ashima Makol, Oliver Distler, Hector Chinoy, Vikas Agarwal, Rohit Aggarwal, Latika Gupta, Elena Nikiphorou, COVAD Study Group
Dátum:2023
ISSN:1462-0324 1462-0332
Megjegyzések:Objectives: The COVID-19 vaccination in autoimmune diseases (COVAD) study aimed to assess short-term COVID-19 vaccination-related adverse events (AEs) in RA patients. Methods: An online self-reported questionnaire (March-December 2021) was used to capture data related to COVID-19 vaccination-related AEs in RA, other autoimmune rheumatic diseases (AIRDs) (excluding RA and inflammatory myositis), non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs). Descriptive and multivariable regression analyses were performed. Results: Of the 9462 complete respondents, 14.2% (n = 1347) had been diagnosed with RA; they had a mean (s.d.) age of 50.7 (13.7) years, 74.2% were women and 49.3% were Caucasian. In total, 76.9% and 4.2% of patients with RA reported minor and major AEs, respectively. Patients with active and inactive RA had similar AE and hospitalization frequencies. Overall, AEs were reported more frequently by BNT162b2 and mRNA-1273 recipients and less frequently by BBV152 recipients compared with the rest. Major AE and hospitalization frequencies were similar across recipients of different vaccines. Patients receiving methotrexate and hydroxychloroquine reported fewer minor AEs than those patients not on them. Compared with HCs and patients with other AIRDs, patients with RA reported similar total AEs, overall minor AEs, and hospitalizations. Compared with nrAIDs, patients with RA reported lower frequencies of overall AEs, minor AEs (both odds ratio [OR] = 0.7; 95% CI: 0.5, 0.9), and injection site pain (OR = 0.6; 95% CI: 0.5, 0.8) with similar major AE and hospitalization frequencies. Conclusion: Despite the differences in AE frequency across different COVID-19 vaccines, all were well tolerated in patients with RA and were comparable to HCs, providing reassurance as to the safety of COVID-19 vaccination.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Adverse effects
COVID-19
RA
autoimmune diseases
vaccination
Megjelenés:Rheumatology. - 62 : 7 (2023), p. 2366-2376. -
További szerzők:Parodis, Ioannis Joshi, Mrudula Sen, Parikshit Lindblom, Julius Agarwal, Vishwesh Lilleker, James B. Tan, Ai Lyn Nune, Arvind Shinjo, Samuel Katsuyuki Salim, Babur Ziade, Nelly Velikova, Tsvetelina Edgar Gracia-Ramos, Abraham Saavedra, Miguel A. Day, Jessica Makol, Ashima Distler, Oliver Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Nikiphorou, Elena (reumatológus) Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

9.

001-es BibID:BIBFORM120114
035-os BibID:(Scopus)85159682435 (WoS)000961261800002
Első szerző:Naveen, R.
Cím:Systemic sclerosis and COVID-19 vaccine safety : short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey / Naveen R., Thakare Darpan R., Kuwana Masataka, Pauling John D., Day Jessica, Joshi Mrudula, Parodis Ioannis, Sen Parikshit, Jagtap Kshitij, Nikiphorou Elena, Saha Sreoshy, Agarwal Vishwesh, Chatterjee Tulika, Lilleker James B., Kardes Sinan, Milchert Marcin, Gheita Tamer, Salim Babur, Velikova Tsvetelina, Gracia-Ramos Abraham Edgar, Tan Ai Lyn, Nune Arvind, Cavagna Lorenzo, Saavedra Miguel A., Shinjo Samuel Katsuyuki, Ziade Nelly, Knitza Johannes, Distler Oliver, Chinoy, COVAD Study Group, Aggarwal Rohit, Gupta Latika, Agarwal Vikas, Makol Ashima
Dátum:2023
ISSN:0172-8172 1437-160X
Megjegyzések:The safety profile of COVID-19 vaccines is understudied in patients with systemic sclerosis (SSc). We compared short-term adverse events (AEs) 7 days following vaccination in patients with SSc vs other rheumatic (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). The COVID-19 Vaccination in autoimmune diseases (COVAD) self-reporting e-survey was circulated by a group of > 110 collaborators in 94 countries from March to December 2021. AEs were analyzed between different groups using regression models. Of 10,679 complete respondents [73.8% females, mean age 43 years, 53% Caucasians], 478 had SSc. 83% had completed two vaccine doses, Pfizer-BioNTech (BNT162b2) (51%) was the most common. Minor and major AEs were reported by 81.2% and 3.3% SSc patients, respectively, and did not differ significantly with disease activity or different vaccine types, though with minor symptom differences. Frequencies of AEs were not affected by background immunosuppression, though SSc patients receiving hydroxychloroquine experienced fatigue less commonly (OR 0.4; 95% CI 0.2-0.8). Frequency of AEs and hospitalisations were similar to other AIRDs, nrAIDs, and HC except a higher risk of chills (OR 1.3; 95% CI 1.0-1.7) and fatigue (OR 1.3; 95% CI 1.0-1.6) compared to other AIRDs. COVID-19 vaccines were largely safe and well tolerated in SSc patients in the short term. Background immunosuppression and disease activity did not influence the vaccination-related short-term AEs.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Adverse events
Autoimmune diseases
COVID-19
Systemic sclerosis
Vaccination
Megjelenés:Rheumatology International. - 43 : 7 (2023), p. 1265-1275. -
További szerzők:Thakare, Darpan R. Kuwana, Masataka Pauling, John D. Day, Jessica Joshi, Mrudula Parodis, Ioannis Sen, Parikshit Jagtap, Kshitij Nikiphorou, Elena (reumatológus) Saha, Sreoshy Agarwal, Vishwesh Chatterjee, Tulika Lilleker, James B. Kardes, Sinan Milchert, Marcin Gheita, Tamer A. Salim, Babur Velikova, Tsvetelina Gracia-Ramos, Abraham Edgar Tan, Ai Lyn Nune, Arvind Cavagna, Lorenzo Saavedra, Miguel A. Shinjo, Samuel Katsuyuki Ziade, Nelly Knitza, Johannes Distler, Oliver Aggarwal, Rohit Gupta, Latika Agarwal, Vikas Makol, Ashima Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

10.

001-es BibID:BIBFORM120113
Első szerző:Naveen, R.
Cím:Safety and tolerance of vaccines against SARS-CoV-2 infection in systemic lupus erythematosus : results from the COVAD study / Naveen R., Nikiphorou Elena, Joshi Mrudula, Sen Parikshit, Lindblom Julius, Agarwal Vishwesh, Lilleker James B., Tan Ai Lyn, Salim Babur, Ziade Nelly, Velikova Tsvetelina, Gracia-Ramos Abraham Edgar, Kuwana Masataka, Day Jessica, Makol Ashima, Distler Oliver, Chinoy Hector, Traboco Lisa S., Wibowo Suryo Anggoro Kusumo, Tehozol Erick Adrian Zamora, Serrano Jorge Rojas, García-De La Torre Ignacio, COVAD Study Group, Aggarwal Rohit, Gupta Latika, Agarwal Vikas, Parodis Ioannis
Dátum:2023
ISSN:1462-0324 1462-0332
Megjegyzések:Objective: To determine COVID-19 vaccine-related adverse events (AEs) in the seven-day post-vaccination period in patients with SLE vs autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HC). Methods: Data were captured through the COVID-19 Vaccination in Autoimmune Diseases (COVAD) questionnaire (March-December 2021). Multivariable regression models accounted for age, gender, ethnicity, vaccine type and background treatment. Results: Among 9462 complete respondents, 583 (6.2%) were SLE patients (mean age: 40.1 years; 94.5% females; 40.5% Asian; 42.9% Pfizer-recipients). Minor AEs were reported by 83.0% of SLE patients, major by 2.6%, hospitalization by 0.2%. AE and hospitalization frequencies were similar between patients with active and inactive SLE. Rashes were more frequent in SLE patients vs HC (OR; 95% CI: 1.2; 1.0, 1.5), chills less frequent in SLE vs AIRDs (0.6; 0.4, 0.8) and nrAIDs (0.5; 0.3, 0.8), and fatigue less frequent in SLE vs nrAIDs (0.6; 0.4, 0.9). Pfizer-recipients reported higher overall AE (2.2; 1.1, 4.2) and injection site pain (2.9; 1.6, 5.0) frequencies than recipients of other vaccines, Oxford/AstraZeneca-recipients more body ache, fever, chills (OR: 2.5, 3.0), Moderna-recipients more body ache, fever, chills, rashes (OR: 2.6, 4.3). Hospitalization frequencies were similar across vaccine types. AE frequencies were similar across treatment groups, although chills were less frequent in antimalarial users vs non-users (0.5; 0.3, 0.9). Conclusion: While COVID-19 vaccination-related AEs were reported by four-fifths of SLE patients, those were mostly minor and comparable to AEs reported by healthy individuals, providing reassurance regarding COVID-19 vaccination safety in SLE.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19
adverse events
rheumatology
systemic lupus erythematosus
vaccine
Megjelenés:Rheumatology. - 62 : 7 (2023), p. 2453-2463. -
További szerzők:Nikiphorou, Elena (reumatológus) Joshi, Mrudula Sen, Parikshit Lindblom, Julius Agarwal, Vishwesh Lilleker, James B. Tan, Ai Lyn Salim, Babur Ziade, Nelly Velikova, Tsvetelina Gracia-Ramos, Abraham Edgar Kuwana, Masataka Day, Jessica Makol, Ashima Distler, Oliver Chinoy, Hector Traboco, Lisa S. Wibowo, Suryo Anggoro Kusumo Tehozol, Erick Adrian Zamora Serrano, Jorge Rojas García-De La Torre, Ignacio Aggarwal, Rohit Gupta, Latika Agarwal, Vikas Parodis, Ioannis Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

11.

001-es BibID:BIBFORM110887
035-os BibID:(WoS)000999243100001 (Scopus)85180733005
Első szerző:Naveen, R.
Cím:Flares in IIMs and the timeline following COVID-19 vaccination : a combined analysis of the COVAD-1 and 2 surveys / Naveen R., Sen Parikshit, Griger Zoltán, Day Jessica, Joshi Mrudula, Nune Arvind, Nikiphorou Elena, Saha Sreoshy, Tan Ai Lyn, Shinjo Samuel Katsuyuki, Ziade Nelly, Velikova Tsvetelina, Milchert Marcin, Jagtap Kshitij, Parodis Ioannis, Edgar Gracia-Ramos Abraham, Cavagna Lorenzo, Kuwana Masataka, Knitza Johannes, Chen Yi Ming, Makol Ashima, Agarwal Vishwesh, Patel Aarat, Pauling John D., Wincup Chris, Barman Bhupen, Zamora Tehozol Erick Adrian, Serrano Jorge Rojas, García-De La Torre Ignacio, Colunga-Pedraza Iris J., Merayo-Chalico Javier, Chibuzo Okwara Celestine, Katchamart Wanruchada, Goo Phonpen Akawatcharangura, Shumnalieva Russka, Hoff Leonardo Santos, Kibbi El Lina, Halabi Hussein, Vaidya Binit, Shaharir Syahrul Sazliyana, Hasan A. T. M. Tanveer, Dey Dzifa, Gutiérrez Carlos Enrique Toro, Caballero-Uribe Carlo Vinicio, Lilleker James B., Salim Babur, Gheita Tamer, Chatterjee Tulika, Distler Oliver, Saavedra Miguel A., COVAD study group, Chinoy Hector, Agarwal Vikas, Aggarwal Rohit, Gupta Latika
Dátum:2024
ISSN:1462-0324 1462-0332
Megjegyzések:Objectives: Disease flares in the post COVID-19 vaccination period represent a prominent concern, though risk factors are poorly understood. We studied these flares among patients with idiopathic inflammatory myopathies (IIMs) and other autoimmune rheumatic diseases (AIRDs). Methods: The COVAD-1 and -2 global surveys were circulated in early 2021 and 2022 respectively, and we captured demographics, comorbidities, AIRDs details, COVID-19 infection history, and vaccination details.Flares of IIMs were defined as a. patient self-reported, b. immunosuppression (IS) denoted, c. clinical sign directed, and d. with >7.9-point MCID worsening of PROMISPF10a score. Risk factors of flares were analyzed using regression models. Results: Of 15165 total respondents, 1278 IIMs (age 63 years, 70.3% female, 80.8% Caucasians), and 3453 AIRDs were included. Flares of IIM were seen in 9.6%, 12.7%, 8.7%, and 19.6% patients by definitions a-d respectively with a median time to flare of 71.5 (10.7-235) days, similar to AIRDs. Patients with active IIMs pre-vaccination (OR:1.2; 95%CI:1.03-1.6, p = 0.025) were prone to flares, while those receiving Rituximab (OR:0.3; 95%CI:0.1-0.7, p = 0.010) and Azathioprine (OR:0.3, 95%CI:0.1-0.8, p = 0.016) were at lower risk. Female gender and comorbidities predisposed to flares requiring changes in immunosuppression. Asthma (OR: 1.62; 95%CI: 1.05-2.50, p = 0.028) and higher pain VAS (OR: 1.19; 95%CI: 1.11-1.27, p < 0.001) were associated with disparity between self-reported and IS-denoted flares. Conclusion: A diagnosis of IIMs confers an equal risk of flares in the post COVID-19 vaccination period to AIRDs, with active disease, female gender, and comorbidities conferring a higher risk. Disparity between patient and physician reported outcomes represents a future avenue for exploration.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19 Vaccines
Disease Exacerbation
Idiopathic Inflammatory Myopathies
Patient Reported Outcomes
Megjelenés:Rheumatology. - 63 : 1 (2024), p. 127-139. -
További szerzők:Sen, Parikshit Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) Day, Jessica Joshi, Mrudula Nune, Arvind Nikiphorou, Elena (reumatológus) Saha, Sreoshy Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Jagtap, Kshitij Parodis, Ioannis Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Chen, Yi Ming Makol, Ashima Agarwal, Vishwesh Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Zamora Tehozol, Erick Adrian Serrano, Jorge Rojas García-De La Torre, Ignacio Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Hoff, Leonardo Santos El Kibbi, Lina Halabi, Hussein Vaidya, Binit Shaharir, Syahrul Sazliyana Hasan, A. T. M. Tanveer Dey, Dzifa Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Distler, Oliver Saavedra, Miguel A. Chinoy, Hector Agarwal, Vikas Aggarwal, Rohit Gupta, Latika Nagy-Vincze Melinda (1985-) (orvos) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

12.

001-es BibID:BIBFORM109287
Első szerző:Sen, Parikshit
Cím:Vaccine hesitancy decreases in rheumatic diseases, long-term concerns remain in myositis : a comparative analysis of the COVAD surveys / Parikshit Sen, Naveen R., Nazanin Houshmand, Siamak Moghadam Kia, Mrudula Joshi, Sreoshy Saha, Kshitij Jagtap, Vishwesh Agarwal, Arvind Nune, Elena Nikiphorou, Ai Lyn Tan, Samuel Katsuyuki Shinjo, Nelly Ziade, Tsvetelina Velikova, Marcin Milchert, Ioannis Parodis, Abraham Edgar Gracia-Ramos, Lorenzo Cavagna, Masataka Kuwana, Johannes Knitza, Ashima Makol, Aarat Patel, John D. Pauling, Chris Wincup, Bhupen Barman, Erick Adrian Zamora Tehozol, Jorge Rojas Serrano, Ignacio Garcia-De La Torre, Iris J. Colunga-Pedraza, Javier Merayo-Chalico, Okwara Celestine Chibuzo, Wanruchada Katchamart, Phonpen Akawatcharangura Goo, Russka Shumnalieva, Yi-Ming Chen, Leonardo Santos Hoff, Lina El Kibbi, Hussein Halabi, Binit Vaidya, Syahrul Sazliyana Shaharir, A. T. M. Tanveer Hasan, Dzifa Dey, Carlos Enrique Toro Gutièrrez, Carlo Vinicio Caballero-Uribe, James B. Lilleker, Babur Salim, Tamer Gheita, Tulika Chatterjee, Oliver Distler, Miguel A. Saavedra, Jessica Day, Hector Chinoy, COVAD Study Group
Dátum:2023
ISSN:1462-0324 1462-0332
Megjegyzések:Objective: COVID-19 vaccines have a favorable safety profile in patients with autoimmune rheumatic diseases (AIRDs) such as idiopathic inflammatory myopathies (IIMs), however hesitancy continues to persist among these patients.Therefore, we studied the prevalence, predictors, and reasons for hesitancy in patients with IIMs, other AIRDs, non-rheumatic autoimmune diseases (nrAIDs) and healthy controls (HCs), using data from the two international COVID-19 Vaccination in Autoimmune Diseases (COVAD) e-surveys. Methods: The 1st and 2nd COVAD patient self-reported e-surveys were circulated from March to December 2021, and February to June 2022 (ongoing). We collected data on demographics, comorbidities, COVID-19 infection and vaccination history, reasons for hesitancy, and patient reported outcomes. Predictors of hesitancy were analyzed using regression models in different groups. Results: We analyzed data from 18,882 (COVAD-1) and 7666 (COVAD-2) respondents. Reassuringly, hesitancy decreased from 2021 (16.5%) to 2022 (5.1%) [OR 0.26; 95%CI: 0.24-0.30, p < 0.001]. However, concerns/fear over long-term safety had increased [OR 3.6;95% CI:2.9-4.6, p < 0.01].We noted with concern greater skepticism over vaccine science among patients with IIMs than AIRDs [OR:1.8; 95%CI: 1.08-3.2, p = 0.023] and HCs [OR: 4; 95%CI: 1.9-8.1, p < 0.001], as well as more long-term safety concerns/fear [IIMs vs AIRDs; OR: 1.9; 95%CI: 1.2-2.9, p = 0.001; IIMs vs HCs; OR: 5.4 95%CI: 3-9.6), p < 0.001].Caucasians [OR 4.2 (1.7-10.3)] were likely to be more hesitant, while those with better PROMIS physical health score were less hesitant [OR 0.9 (0.8-0.97)]. Conclusion: Vaccine hesitancy has decreased from 2021 to 2022, long-term safety concerns remain among patients with IIMs, particularly in Caucasians and those with poor physical function.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
COVID-19 vaccines
Idiopathic Inflammatory Myopathies
autoimmune disease
registries
vaccine hesitancy
Megjelenés:Rheumatology. - 62 : 10 (2023), p. 3291-3301. -
További szerzők:Naveen, R. Houshmand, Nazanin Moghadam Kia, Siamak Joshi, Mrudula Saha, Sreoshy Jagtap, Kshitij Agarwal, Vishwesh Nune, Arvind Nikiphorou, Elena (reumatológus) Tan, Ai Lyn Shinjo, Samuel Katsuyuki Ziade, Nelly Velikova, Tsvetelina Milchert, Marcin Parodis, Ioannis Gracia-Ramos, Abraham Edgar Cavagna, Lorenzo Kuwana, Masataka Knitza, Johannes Makol, Ashima Patel, Aarat Pauling, John D. Wincup, Chris Barman, Bhupen Zamora Tehozol, Erick Adrian Rojas Serrano, Jorge García-De La Torre, Ignacio Colunga-Pedraza, Iris J. Merayo-Chalico, Javier Chibuzo, Okwara Celestine Katchamart, Wanruchada Akawatcharangura Goo, Phonpen Shumnalieva, Russka Chen, Yi-Ming Hoff, Leonardo Santos El Kibbi, Lina Halabi, Hussein Vaidya, Binit Sazliyana Shaharir, Syahrul Hasan, A. T. M. Tanveer Dey, Dzifa Gutiérrez, Carlos-Enrique Toro Caballero-Uribe, Carlo Vinicio Lilleker, James B. Salim, Babur Gheita, Tamer A. Chatterjee, Tulika Distler, Oliver Saavedra, Miguel A. Day, Jessica Chinoy, Hector Nagy-Vincze Melinda (1985-) (orvos) Griger Zoltán (1979-) (belgyógyász, allergológus és klinikai immunológus, reumatológus) COVAD Study Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 2 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.